SYFbc1c468362564e8c85e5503815b5d3a7

UnknownPhase 1

OPEN-LABEL PALATABILITY STUDY OF A NOVEL ORODISPERSIBLE PARA...

Farmalider S.A.Source

Compare

Study Type

interventional

Reported enrollment (type unavailable)

N/A

Locations

1 country

Sites

1

Registry Overview

Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.

Recruitment status: unknown
Reported enrollment (type unavailable): Not reported
Study completion date: Not reported
Date not reported
Listed locations: 1 countries · 1 sites

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.

First Submitted
October 23, 2025
Actual (reported)

Conditions

Healthy volunteers

Sponsors & Collaborators

Farmalider S.A.
Industrylead

Study Sites (1)

Hospital Clinico San Carlos

Madrid, 28040, Spain

Antonio Portolés Perez34917044146 ufase1fc.hcsc@salud.madrid.org

Central Study Contacts

Carlos Calandria

+34916612335 carloscalandria@farmalider.com

Study Design

Study Type: interventional
Phase: phase 1

Study Record Dates

First Submitted

October 23, 2025

Source record

Download the complete CTIS (EMA) record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.

Source: European Medicines Agency (EMA), Clinical Trials Information System (CTIS). Original record and public documents are available on CTIS.

JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.

Registry identifier: 2025-524274-41-00
Data provider: European Medicines Agency (EMA)
Normalization version: ctis-v1

Open registry record

Source retrieved: 2026-10-31 06:40:30 UTC

Locations

ES(1)

SYF66be4531f99d43cab55099002fdc133b

Randomized, crossover, two-period, two-treatment, comparative bioavailability study of ibuprofen (arginine) granules for oral solution, developed by Farmalider, S.A., and Espidifen® granules for oral solution, administered in single dose of 600 mg to healthy subjects under fasting conditions.

Phase 1Unknown

SYF25157bd09378453d835d3103e61461ad

Randomized, crossover, comparative bioavailability study of two tadalafil formulations (oral suspension and film-coated tablets) after a single oral dose of 20 mg under fed conditions in healthy male volunteers.

Phase 1Recruiting

SYFe20e16e6874e4d678e904f5729775b7f

Pilot, randomized, crossover, comparative bioavailability study of two tadalafil formulations (oral suspension and film-coated tablets) after a single oral dose of 20 mg under fasting conditions in healthy male volunteers.

Phase 1Unknown

SYF6ab8e0b3d0f64f30b69baf64731ae780

Randomized, open-label, three-period crossover study on the palatability of oral dispersible formulations of Zonisamide in healthy volunteers.

Phase 1Unknown

SYFa280e1e28da94c1f89b7f40ffd5fec6a

Bioequivalence clinical trial of two formulations of Pregabalin 300 mg.

Phase 1Unknown

SYF857528641dbe4c50bfb35354affc65e1

Bioequivalence clinical trial of two formulations of rosuvastatin/ezetimibe.

Phase 1Unknown

NCT02633696

Study to Investigate the Absolute Bioavailability of Oral Sylibin